Navigation Links
Cardiome to Hold Conference Call
Date:4/8/2009

NASDAQ: CRME TSX: COM

VANCOUVER, April 8 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) today announced that a teleconference call and webcast will be held at 9:00am Eastern (6:00am Pacific) on Thursday, April 9, 2009 to discuss 2008 financial results and the recently announced agreement with Merck & Co., Inc.

To access the conference call, please dial 416-695-7806 or 888-789-9572 and reference conference 3221183. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome's website at www.cardiome.com.

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through May 9, 2009. Please dial 416-695-5800 or 800-408-3053 and enter code 6640523 follwed by the number sign to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.


'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CardioCareLive.com, First Ever Online Cardiometabolic Conference, Revolutionizes Continuing Medical Education for Cardiovascular Healthcare Professionals
2. Cardiome Reports 2008 Results
3. CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today
4. Noninvasive Medical Technologies to Exhibit at CardioCareLive - A Premier Cardiometabolic Conference
5. Cardiome Discloses Chairman And CEOs Involuntary Share Sale
6. Cardiome Provides Regulatory Update
7. Cardiome To Release Second Quarter Results And Hold Conference Call
8. Cardiome Announces Preferred Share Financing
9. Cardiome Announces Positive Phase 2b Results For Oral Vernakalant
10. Cardiome To Hold Conference Call
11. Cardiome Reports First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, S.C., wants to ... wife’s hand was damaged in a firework accident, so she couldn’t grip a pen ... problems." , He then designed and created a prototype for the HELPEN HAND, a ...
(Date:5/22/2017)... ... May 22, 2017 , ... Faithfully following pop culture, people today are forever ... and shaped through fitness programs. It carries on to skin nourished, pampered and nurtured ... irresistible, radiant smile. CDA has found that just like a perfectly cut ...
(Date:5/21/2017)... ... ... 52, was found dead on the night of Wednesday, May 17, 2017. It can be ... rock industry would take his own life, but the extremely talented and admired singer ... role in the death of Chris Cornell . , Depression and Drug Use , ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... text designs created specifically for use in Final Cut Pro X. The business-oriented ... media productions. Pixel Film Studios’ ProParagraph Corporate will deliver a professional and distinguished ...
(Date:5/21/2017)... ... May 21, 2017 , ... Florida Pain Relief Group, ... of its newest location at 109 Silver Palm Ave., Melbourne, on Monday, May 22. ... With the opening of the Melbourne practice, PPOA operates 23 pain management clinics in ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... , May 18, 2017  Two Bayer U.S. ... Association (HBA) during its recent 28 th ... City.  The event showcases HBA,s longstanding mission of furthering ... of healthcare. Cindy Powell-Steffen , senior ... U.S. Radiology division, and Libby Howe , a ...
(Date:5/15/2017)... ATLANTA , May 15, 2017  Amy Baxter ... the industry leader in noninvasive pain relief, was awarded ... MM&M magazine. Baxter was recognized at the MM&M ... New York City on May 10, ... helping the biopharma industry go "beyond the pill."  ...
(Date:5/12/2017)... May 12, 2017  The China and Canada ... that consumes less water, energy and detergent, and features a powerful ... LaughingU, a shoebox-sized washing machine that washes and sanitizes women,s panties ... ... is compact, and does not require an external water inlet. ...
Breaking Medicine Technology: